PDF
Engineered CARD11–PIK3R3 T-cell therapies as weapons of cancer mass destruction
Wanlu Zhang1, Min Wu2,3(
), Yongye Huang1,3()
PDF
Engineered CARD11–PIK3R3 T-cell therapies as weapons of cancer mass destruction
), Yongye Huang1,3()| 1 | J Garcia, J Daniels, Y Lee, et al. Naturally occurring T cell mutations enhance engineered T cell therapies. Nature. 2024;626(7999):626-634. |
| 2 | EA Stadtmauer, JA Fraietta, MM Davis, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365. |
| 3 | J Middelburg, M Sluijter, G Schaap, et al. T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors. Nat Commun. 2024;15(1):48. |
| 4 | R Eferl, EF Wagner. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3(11):859-868. |
| 5 | KPM Suijkerbuijk, MJM van Eijs, F van Wijk, AMM Eggermont. Clinical and translational attributes of immune-related adverse events. Nat Cancer. 2024;5(4):557-571. |
/
| 〈 |
|
〉 |
AI Summary
